Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.

Zacks Investment Research • Jun 5, 2026

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

Business Wire • May 12, 2026

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.

Zacks Investment Research • Apr 30, 2026

Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out

Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.

Investors Business Daily • Apr 30, 2026

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Seeking Alpha • Apr 30, 2026

Glaukos Announces First Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.

Business Wire • Apr 29, 2026

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Apr 30, 2026

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

Zacks Investment Research • Apr 29, 2026

Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy

GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.

Zacks Investment Research • Apr 16, 2026

Glaukos Announces the Release of its 2025 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. “I am prou.

Business Wire • Apr 16, 2026